Cytokine Storms Articles & Analysis: Older
27 news found
Its flagship product, CytoSorb®, is approved in the European Union with distribution in more than 70 countries around the world as an extracorporeal cytokine adsorber designed to reduce the “cytokine storm” or “cytokine release syndrome” seen in common critical illnesses that may result in massive ...
Its flagship product, CytoSorb®, is approved in the European Union with distribution in more than 70 countries around the world as an extracorporeal cytokine adsorber designed to reduce the “cytokine storm” or “cytokine release syndrome” seen in common critical illnesses that may result in massive ...
Its flagship product, CytoSorb®, is approved in the European Union with distribution in more than 70 countries around the world as an extracorporeal cytokine adsorber designed to reduce the “cytokine storm” or “cytokine release syndrome” seen in common critical illnesses that may result in massive ...
Capricor's lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy that is currently in clinical development for treating Duchenne muscular dystrophy and the cytokine storm associated with COVID-19. Capricor is also developing its exosome technology as a next-generation therapeutic platform. ...
Capricor's lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy that is currently in clinical development for treating Duchenne muscular dystrophy and the cytokine storm associated with COVID-19. Capricor is also developing its exosome technology as a next-generation therapeutic platform. ...
Capricor's lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy that is currently in clinical development for treating Duchenne muscular dystrophy and the cytokine storm associated with COVID-19. Capricor is also developing its exosome technology as a next-generation therapeutic platform. ...
Capricor's lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy that is currently in clinical development for treating Duchenne muscular dystrophy and the cytokine storm associated with COVID-19. Capricor is also developing its exosome technology as a next-generation therapeutic platform. ...
Creative Proteomics Cytokine recently announced Disease Cytokine Assays to help researchers obtain higher quality scientific research data. ...
BenevolentAI scientists then supplemented this with relevant biological context so that the network represented, at a molecular level, how SARS-CoV-2 enters and infects cells, as well as the potentially lethal inflammatory response, the so-called ‘cytokine storm’. Focusing on these aspects, the scientific team short-listed 40 drugs, finally ...
In my many years in the operating room I have consistently observed the benefits of cytokine removal with CytoSorb in complex cardiac operations such as acute endocarditis or complex aortic surgery and also witnessed the significant reductions in bleeding when using CytoSorb in urgent operations on patients on antithrombotic drugs like ticagrelor and rivaroxaban. ...
However, ECMO does not remove the circulating inflammatory cytokines and other toxins that can contribute to ongoing injury to the lungs and other vital organs and prevent or delay healing. ...
The Vent2Cool medical device shields the brain and heart of resuscitated cardiac arrest patients from the reperfusion-induced cytokine storm. Vent2Cool improves survival and morbidity outcomes of Post Cardiac Arrest Syndrome by inducing ultra-rapid therapeutic hypothermia, reaching 33°C within minutes versus hours with current hypothermia devices. ...
Its flagship product, CytoSorb®, is approved in the European Union with distribution in 68 countries around the world as an extracorporeal cytokine adsorber designed to reduce the “cytokine storm” or “cytokine release syndrome” seen in common critical illnesses that may result in massive inflammation, ...
Its flagship product, CytoSorb®, is approved in the European Union with distribution in 68 countries around the world as an extracorporeal cytokine adsorber designed to reduce the “cytokine storm” or “cytokine release syndrome” seen in common critical illnesses that may result in massive inflammation, ...
The investigators concluded that although intraoperative hemoadsorption reduced plasma cytokines at the end of cardiopulmonary bypass, it did not reduce the severity of post-operative organ dysfunction as observed by the change in mean SOFA (Sequential Organ Failure Assessment) score over nine days. ...
Additionally, LEA™ was shown in preclinical testing to decrease inflammatory cytokine (TNFα, IL-1β, CXCL5 and IL-8) levels at concentrations 50 times less than toxic levels. LEA™ was shown to be effective in an in vitro photoaging experiment with anti-inflammatory action based on IL-6 inhibition against UVA irradiation in cultured human dermal fibroblasts ...
“Mesenchymal stem cells (“MSCs”) have immunomodulatory and tissue regenerative properties, secreting anti-inflammatory cytokines, inhibiting monocyte differentiation, and regulating the function and proliferation of immune cells,” said Lev Verkh, PhD, Stemedica’s Chief Regulatory & Clinical Development Officer. “Our data treating severe and ...
Additionally, LEA™ was shown in preclinical testing to decrease inflammatory cytokine (TNFα, IL-1β, CXCL5 and IL-8) levels at concentrations 50 times less than toxic levels. LEA™ was shown to be effective in an in vitro photoaging experiment with anti-inflammatory action based on IL-6 inhibition against UVA irradiation in cultured human dermal fibroblasts ...
The study found improved inflammatory modulation, and 88 percent of patients had a significant reduction in acute phase reactants (markers for reductions in inflammation) which resulted in a reduced “cytokine storm.” Researchers noted that these patients experienced quicker extubation, less lung trauma and less oxygen toxicity. ...
Such pathogens can contribute to the cytokine storm and sepsis, which are the major causes of mortality in COVID-19 patients,” said Dr. ...